Wisconsin Offers a 25% Tax Incentive for Diabetes Cure Investments, Announces RMS
In the heart of Madison, Wisconsin, Regenerative Medical Solutions, Inc. (RMS) is making waves in the medical world with its groundbreaking approach to diabetes treatment. The company, which specialises in regenerative medicine and stem cell therapy, is developing a potential cure for diabetes using human-induced pluripotent stem cells (iPSCs) to create islet-like clusters (ILCs).
This innovative therapy offers a promising alternative to existing diabetes treatments, eliminating the need for organ donors, heavy immunosuppressive drugs, and their severe side effects. Moreover, RMS's approach promises to eliminate the need for anti-rejection drugs in diabetes treatment, a significant leap forward in diabetes care.
The Wisconsin Economic Development Corporation (WEDC) has shown its support for this promising venture by approving a 25% tax credit for investors in RMS. For every dollar invested by a Wisconsin investor, they can expect to receive 25 cents in the form of a tax credit. This incentive creates a favourable environment for investors interested in the diabetes cure marketplace within Wisconsin.
RMS's commitment to ethical, non-embryonic stem cell therapies aligns with the global movement towards more responsible and sustainable medical practices. The company's CEO, Anthony Kolton, expressed hope for all diabetes patients, stating that the development of a working diabetes cure brings hope and offers investors a 25% income tax credit.
As the field of regenerative medicine focusing on stem cell therapies and related innovations continues to advance, RMS's diabetes cure development appears to be part of an active and promising sector. Clinical trials show potential for functional cures, particularly in type 1 diabetes, involving stem cell-derived islet transplantation combined with immunosuppressive therapies to enhance graft survival and insulin independence.
For potential investors, engaging with local biotech incubators or medical research institutions in Wisconsin that specialise in regenerative medicine and diabetes research can provide valuable insights. Investors can also monitor clinical trials and partnerships in regenerative diabetes therapies for potential investment opportunities.
As of August 2025, specific direct contact or investment pathway for Regenerative Medical Solutions is not publicly available. However, investors can inquire via Wisconsin’s local biotech and regenerative medicine networks or WEDC for the latest specific opportunities.
Regenerative Medical Solutions, Inc. (RMS) invites interested investors to support its mission and play an integral role in bringing this pioneering diabetes cure to market. With its headquarters in Madison, Wisconsin, RMS is poised to make a significant impact on the lives of millions of people living with diabetes.
[1] Clinical Trials in Stem Cell-Based Therapies for Diabetes [2] Stem Cell-Derived Islet Organoids for Diabetes Therapy: Progress and Challenges [3] Wisconsin Economic Development Corporation - Investment Tax Credit Program
- RMS's approach to diabetes treatment, involving human-induced pluripotent stem cells and islet-like clusters, is a potential cure for diabetes that eliminates the need for organ donors and heavy immunosuppressive drugs.
- The CEO of RMS, Anthony Kolton, expressed hope for all diabetes patients and offered investors a 25% income tax credit for supporting the company's mission.
- RMS's commitment to ethical, non-embryonic stem cell therapies aligns with the global movement towards more responsible and sustainable medical practices.
- Clinical trials show potential for functional cures, particularly in type 1 diabetes, involving stem cell-derived islet transplantation combined with immunosuppressive therapies.
- Investors can engage with local biotech incubators, medical research institutions, or the Wisconsin Economic Development Corporation to gain insights into RMS's diabetes cure development and potential investment opportunities.
- As of August 2025, specific direct contact or investment pathway for Regenerative Medical Solutions is not publicly available, but interested investors can inquire via Wisconsin’s local biotech and regenerative medicine networks or WEDC for the latest specific opportunities.
